The Pipeline

Our lead product candidate is relugolix, an oral, once-daily, small molecule that acts as a GnRH receptor antagonist. We have three clinical programs for relugolix consisting of five international Phase 3 clinical trials, two in women with heavy menstrual bleeding associated with uterine fibroids (LIBERTY 1 & 2), two in women with endometriosis-associated pain (SPIRIT 1 & 2), and one in men with advanced prostate cancer (HERO).

Our second product candidate is MVT-602, an oligopeptide kisspeptin-1 receptor agonist. We are developing MVT-602 for the treatment of female infertility as part of assisted reproduction.

 
Compound Indication Preclinical Phase 1 Phase 2 Phase 3
Relugolix
Uterine Fibroids - Heavy Menstrual Bleeding Phase 2 Complete
Endometriosis - Pain Phase 2 Complete
Advanced Prostate Cancer Phase 2 Complete
MVT-602
Female Infertility as Part of Assisted Reproduction Entering Phase 1
Relugolix - Japanese Development (Takeda)
Uterine Fibroids - Heavy Menstrual Bleeding Phase 3 Complete
Uterine Fibroids - Pain Phase 3 Complete

Clinical TRIALS

To learn more about Myovant’s clinical trials, please visit www.clinicaltrials.gov. To learn more about those trials that are still enrolling, please visit www.myspiritstudy.com (for pain associated with endometriosis).